BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16432172)

  • 1. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy.
    Lee YK; Isham CR; Kaufman SH; Bible KC
    Mol Cancer Ther; 2006 Jan; 5(1):138-48. PubMed ID: 16432172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
    Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
    Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
    Gao N; Dai Y; Rahmani M; Dent P; Grant S
    Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1.
    Ma Y; Cress WD; Haura EB
    Mol Cancer Ther; 2003 Jan; 2(1):73-81. PubMed ID: 12533675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
    Bible KC; Kaufmann SH
    Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
    Chen R; Keating MJ; Gandhi V; Plunkett W
    Blood; 2005 Oct; 106(7):2513-9. PubMed ID: 15972445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
    Alas S; Bonavida B
    Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
    Gojo I; Zhang B; Fenton RG
    Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitor tyrphostin AG490 triggers both apoptosis and autophagy by reducing HSF1 and Mcl-1 in PEL cells.
    Granato M; Chiozzi B; Filardi MR; Lotti LV; Di Renzo L; Faggioni A; Cirone M
    Cancer Lett; 2015 Oct; 366(2):191-7. PubMed ID: 26184999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
    Pei XY; Dai Y; Grant S
    Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive activation of STAT transcription factors in acute myelogenous leukemia.
    Spiekermann K; Biethahn S; Wilde S; Hiddemann W; Alves F
    Eur J Haematol; 2001 Aug; 67(2):63-71. PubMed ID: 11722592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.
    Oshiro MM; Landowski TH; Catlett-Falcone R; Hazlehurst LA; Huang M; Jove R; Dalton WS
    Clin Cancer Res; 2001 Dec; 7(12):4262-71. PubMed ID: 11751528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.
    Isomoto H; Kobayashi S; Werneburg NW; Bronk SF; Guicciardi ME; Frank DA; Gores GJ
    Hepatology; 2005 Dec; 42(6):1329-38. PubMed ID: 16317687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils.
    Epling-Burnette PK; Zhong B; Bai F; Jiang K; Bailey RD; Garcia R; Jove R; Djeu JY; Loughran TP; Wei S
    J Immunol; 2001 Jun; 166(12):7486-95. PubMed ID: 11390502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
    Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
    Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
    Kitada S; Zapata JM; Andreeff M; Reed JC
    Blood; 2000 Jul; 96(2):393-7. PubMed ID: 10887097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro.
    Huang C; Cao J; Huang KJ; Zhang F; Jiang T; Zhu L; Qiu ZJ
    Cancer Sci; 2006 Dec; 97(12):1417-23. PubMed ID: 17054436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a JAK inhibitor, AG490, on proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2Z.
    Wu MH; Chen XY; Cai KR
    Ai Zheng; 2009 Jan; 28(1):24-8. PubMed ID: 19448411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.
    Matranga CB; Shapiro GI
    Cancer Res; 2002 Mar; 62(6):1707-17. PubMed ID: 11912144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
    Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
    Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.